Results 291 to 300 of about 128,830 (335)

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer   +14 more
wiley   +1 more source

Light from Light

open access: yesJournal of Religion & Film, 2019
openaire   +1 more source

Light of light

open access: yesJournal of Religion & Film
openaire   +1 more source

Home - About - Disclaimer - Privacy